X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/ns-pharma-announces-research-alliance-with-mina-therapeutics-to-develop-therapies-for-rare-diseases-of-the-central-nervous-system-302106379.html
https://www.biospectrumasia.com/news/25/24044/japans-ns-pharma-uk-based-mina-therapeutics-lay-focus-on-rare-diseases-of-central-nervous-system.html
https://www.prnewswire.com/news-releases/ns-pharma-inc-shares-new-viltepso-viltolarsen-data-at-the-mda-clinical--scientific-conference-2024-302080958.html
https://www.prnewswire.com/news-releases/the-european-commission-grants-orphan-drug-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-302039294.html
https://www.prnewswire.com/news-releases/ns-089ncnp-02-receives-orphan-drug-designation-from-the-european-commission-for-the-treatment-of-duchenne-muscular-dystrophy-302020698.html
https://www.prnewswire.com/news-releases/ns-089ncnp-02-preclinical-data-published-in-molecular-therapy-nucleic-acids-301958537.html
https://www.prnewswire.com/news-releases/ns-018-an-investigational-treatment-for-myelofibrosis-receives-orphan-drug-designation-from-the-european-commission-301895312.html
https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-ns-089ncnp-02-for-the-treatment-of-duchenne-muscular-dystrophy-301894119.html
https://www.prnewswire.com/news-releases/ns-pharma-announces-fda-clearance-to-initiate-a-phase-iii-study-for-ns-050ncnp-03-an-exon-50-skipping-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301851575.html
https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-four-year-clinical-trial-data-published-in-the-journal-of-neuromuscular-diseases-301819073.html
Market Place
Share 
